Literature DB >> 19084155

The risk of developing a vancomycin-resistant Enterococcus bloodstream infection for colonized patients.

Cassandra D Salgado1.   

Abstract

EPIDEMIOLOGY: Between 2 to 4 million patients each year develop health care-acquired infections in the United States. Infection resulting from vancomycin-resistant Enterococcus (VRE) is now the second to third most common cause of nosocomial infections in the United States. VRE is most often transmitted by the contaminated hands, clothing, and equipment of health care workers. Patients with VRE bloodstream infections (BSIs) have increased rates of recurrent BSI (16.9% vs 3.7%, respectively, P < .0001), increased crude case fatality rates (relative risk [RR], 2.57; 95% confidence interval [CI]: 2.27-2.91), increased mortality because of bacteremia (RR, 1.79; 95% CI: 1.28-2.50), and increased hospital costs of $27,000 per episode of BSI (P = .04) compared with those with vancomycin-susceptible BSI. Additionally, transfer of the gene responsible for vancomycin resistance to S aureus has been demonstrated in vitro, and reports of clinical infections because of vancomycin-resistant Staphylococcus aureus have been reported from many areas of the world, including the United States. Risk factors for VRE colonization and infection include prolonged length of hospital stay, use of broad-spectrum antibiotics, having an indwelling invasive device, and close proximity to another VRE-colonized or -infected patient; however, risk factors for developing VRE BSI among colonized patients have not been fully described. INFECTION CONTROL: Infection control measures for VRE include antibiotic-usage control, reducing contamination of the environment with proper cleaning and disinfection, and reducing contamination of health care workers by use of contact precautions. Health care-acquired BSIs can also be effectively controlled by closely following central venous line prevention guidelines and complying with the central venous line bundle. Control and prevention of VRE colonization and thus infection would be expected to reduce morbidity, reduce health care costs, and save lives.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19084155     DOI: 10.1016/j.ajic.2008.10.010

Source DB:  PubMed          Journal:  Am J Infect Control        ISSN: 0196-6553            Impact factor:   2.918


  24 in total

Review 1.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

2.  Methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis and Enterococcus faecium active dimeric isobutyrylphloroglucinol from Ivesia gordonii.

Authors:  Marwa H Ahmed; Mohamed Ali Ibrahim; Jin Zhang; Farouk R Melek; Seham S El-Hawary; Melissa R Jacob; Ilias Muhammad
Journal:  Nat Prod Commun       Date:  2014-02       Impact factor: 0.986

3.  Gastrointestinal colonization with a cephalosporinase-producing bacteroides species preserves colonization resistance against vancomycin-resistant enterococcus and Clostridium difficile in cephalosporin-treated mice.

Authors:  Usha Stiefel; Michelle M Nerandzic; Michael J Pultz; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

4.  Repurposing niclosamide for intestinal decolonization of vancomycin-resistant enterococci.

Authors:  Haroon Mohammad; Ahmed AbdelKhalek; Nader S Abutaleb; Mohamed N Seleem
Journal:  Int J Antimicrob Agents       Date:  2018-02-09       Impact factor: 5.283

5.  Predictive utility of swab screening for vancomycin-resistant Enterococcus in selection of empiric antibiotics for Enterococcus sterile-site infections: a retrospective cohort study.

Authors:  Ian Brasg; Marion Elligsen; Derek MacFadden; Nick Daneman
Journal:  CMAJ Open       Date:  2017-08-15

6.  Regional spread and control of vancomycin-resistant Enterococcus faecium and Enterococcus faecalis in Kyoto, Japan.

Authors:  A Matsushima; S Takakura; M Yamamoto; Y Matsumura; M Shirano; M Nagao; Y Ito; Y Iinuma; T Shimizu; N Fujita; S Ichiyama
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-04       Impact factor: 3.267

7.  Enterococcal bacteremia is associated with increased risk of mortality in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Jan Vydra; Ryan M Shanley; Ige George; Celalettin Ustun; Angela R Smith; Daniel J Weisdorf; Jo-Anne H Young
Journal:  Clin Infect Dis       Date:  2012-06-12       Impact factor: 9.079

8.  Prior colonization is associated with increased risk of antibiotic-resistant Gram-negative bacteremia in cancer patients.

Authors:  Aaron S Hess; Michael Kleinberg; John D Sorkin; Giora Netzer; Jennifer K Johnson; Michelle Shardell; Kerri A Thom; Anthony D Harris; Mary-Claire Roghmann
Journal:  Diagn Microbiol Infect Dis       Date:  2014-01-30       Impact factor: 2.803

9.  Cadazolid Does Not Promote Intestinal Colonization of Vancomycin-Resistant Enterococci in Mice.

Authors:  Peter Seiler; Michel Enderlin-Paput; Philippe Pfaff; Maria Weiss; Daniel Ritz; Martine Clozel; Hans H Locher
Journal:  Antimicrob Agents Chemother       Date:  2015-10-26       Impact factor: 5.191

10.  Sequence type 17 is a predictor of subsequent bacteremia in vancomycin-resistant Enterococcus faecium-colonized patients: a retrospective cohort study.

Authors:  Si-Ho Kim; Sun Young Cho; Hye Mee Kim; Kyungmin Huh; Cheol-In Kang; Kyong Ran Peck; Doo Ryeon Chung
Journal:  Antimicrob Resist Infect Control       Date:  2021-07-22       Impact factor: 4.887

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.